
|Articles|July 11, 2017
Meropenem For Ceftazidime-Avibactam—Resistant K. pneumoniae
Researchers from the University of Pittsburgh find a way to successfully treat a patient with ceftazidime-avibactam-resistant Klebsiella pneumoniae.
Advertisement
Clinicians used meropenem to successfully treat a patient with bacteremia due to Klebsiella pneumoniae that carried a mutation in the blaKPC-3 gene, and was resistant to ceftazidime-avibactam.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Developing a COVID-19 Vaccine Alternative
2
Real-World Data Reinforce Effectiveness and Safety of Fecal Microbiota Therapy for Preventing Recurrent C difficile
3
Generic Lenacapavir Could Cost as Little as $25 Per Person Annually
4
Practically Expanding AI's role in Infectious Diseases
5